Genomic architecture of autism spectrum disorder in Qatar: The BARAKA-Qatar Study.
ASD
ASD risk genes
Autism spectrum disorder
BARAKA cohort
De novo variants
Middle Eastern population
SNVs
Whole genome sequencing
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
07 10 2023
07 10 2023
Historique:
received:
02
03
2023
accepted:
04
09
2023
medline:
9
10
2023
pubmed:
8
10
2023
entrez:
7
10
2023
Statut:
epublish
Résumé
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by impaired social and communication skills, restricted interests, and repetitive behaviors. The prevalence of ASD among children in Qatar was recently estimated to be 1.1%, though the genetic architecture underlying ASD both in Qatar and the greater Middle East has been largely unexplored. Here, we describe the first genomic data release from the BARAKA-Qatar Study-a nationwide program building a broadly consented biorepository of individuals with ASD and their families available for sample and data sharing and multi-omics research. In this first release, we present a comprehensive analysis of whole-genome sequencing (WGS) data of the first 100 families (372 individuals), investigating the genetic architecture, including single-nucleotide variants (SNVs), copy number variants (CNVs), tandem repeat expansions (TREs), as well as mitochondrial DNA variants (mtDNA) segregating with ASD in local families. Overall, we identify potentially pathogenic variants in known genes or regions in 27 out of 100 families (27%), of which 11 variants (40.7%) were classified as pathogenic or likely-pathogenic based on American College of Medical Genetics (ACMG) guidelines. Dominant variants, including de novo and inherited, contributed to 15 (55.6%) of these families, consisting of SNVs/indels (66.7%), CNVs (13.3%), TREs (13.3%), and mtDNA variants (6.7%). Moreover, homozygous variants were found in 7 families (25.9%), with a sixfold increase in homozygous burden in consanguineous versus non-consanguineous families (13.6% and 1.8%, respectively). Furthermore, 28 novel ASD candidate genes were identified in 20 families, 23 of which had recurrent hits in MSSNG and SSC cohorts. This study illustrates the value of ASD studies in under-represented populations and the importance of WGS as a comprehensive tool for establishing a molecular diagnosis for families with ASD. Moreover, it uncovers a significant role for recessive variation in ASD architecture in consanguineous settings and provides a unique resource of Middle Eastern genomes for future research to the global ASD community.
Sections du résumé
BACKGROUND
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by impaired social and communication skills, restricted interests, and repetitive behaviors. The prevalence of ASD among children in Qatar was recently estimated to be 1.1%, though the genetic architecture underlying ASD both in Qatar and the greater Middle East has been largely unexplored. Here, we describe the first genomic data release from the BARAKA-Qatar Study-a nationwide program building a broadly consented biorepository of individuals with ASD and their families available for sample and data sharing and multi-omics research.
METHODS
In this first release, we present a comprehensive analysis of whole-genome sequencing (WGS) data of the first 100 families (372 individuals), investigating the genetic architecture, including single-nucleotide variants (SNVs), copy number variants (CNVs), tandem repeat expansions (TREs), as well as mitochondrial DNA variants (mtDNA) segregating with ASD in local families.
RESULTS
Overall, we identify potentially pathogenic variants in known genes or regions in 27 out of 100 families (27%), of which 11 variants (40.7%) were classified as pathogenic or likely-pathogenic based on American College of Medical Genetics (ACMG) guidelines. Dominant variants, including de novo and inherited, contributed to 15 (55.6%) of these families, consisting of SNVs/indels (66.7%), CNVs (13.3%), TREs (13.3%), and mtDNA variants (6.7%). Moreover, homozygous variants were found in 7 families (25.9%), with a sixfold increase in homozygous burden in consanguineous versus non-consanguineous families (13.6% and 1.8%, respectively). Furthermore, 28 novel ASD candidate genes were identified in 20 families, 23 of which had recurrent hits in MSSNG and SSC cohorts.
CONCLUSIONS
This study illustrates the value of ASD studies in under-represented populations and the importance of WGS as a comprehensive tool for establishing a molecular diagnosis for families with ASD. Moreover, it uncovers a significant role for recessive variation in ASD architecture in consanguineous settings and provides a unique resource of Middle Eastern genomes for future research to the global ASD community.
Identifiants
pubmed: 37805537
doi: 10.1186/s13073-023-01228-w
pii: 10.1186/s13073-023-01228-w
pmc: PMC10560429
doi:
Substances chimiques
DNA, Mitochondrial
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
81Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Epilepsia. 2016 Jan;57(1):e18-23
pubmed: 26611353
Genome Res. 2009 Sep;19(9):1553-61
pubmed: 19602639
J Neurodev Disord. 2022 May 23;14(1):32
pubmed: 35606697
NPJ Genom Med. 2022 Feb 21;7(1):13
pubmed: 35190550
Cell. 2019 Sep 5;178(6):1287-1298
pubmed: 31491383
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
Nat Protoc. 2009;4(7):1073-81
pubmed: 19561590
Nat Genet. 2022 Sep;54(9):1320-1331
pubmed: 35982160
Bioinformatics. 2012 Sep 15;28(18):i333-i339
pubmed: 22962449
Front Mol Neurosci. 2022 Oct 13;15:977305
pubmed: 36311025
J Child Psychol Psychiatry. 2019 Dec;60(12):1254-1268
pubmed: 31069792
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
J Child Psychol Psychiatry. 2016 May;57(5):585-95
pubmed: 26709141
Nat Genet. 2014 Aug;46(8):881-5
pubmed: 25038753
J Cell Sci. 2000 Jun;113 ( Pt 11):1851-6
pubmed: 10806096
Nature. 2021 Jan;589(7841):246-250
pubmed: 33442040
BMC Res Notes. 2014 Mar 28;7:188
pubmed: 24673776
Am J Hum Genet. 2012 Sep 7;91(3):408-21
pubmed: 22939633
Hum Mol Genet. 2019 Sep 1;28(17):2937-2951
pubmed: 31152168
J Hum Genet. 2022 Oct;67(10):579-588
pubmed: 35718832
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Bioinformatics. 2015 Aug 15;31(16):2745-7
pubmed: 25851949
Sci Rep. 2020 Aug 20;10(1):14045
pubmed: 32820185
Nucleic Acids Res. 2009 Jan;37(Database issue):D793-6
pubmed: 18842627
Epilepsia. 2016 Jan;57(1):e12-7
pubmed: 26648591
Cell. 2019 Aug 8;178(4):850-866.e26
pubmed: 31398340
J Child Neurol. 2015 Aug;30(9):1147-52
pubmed: 25367918
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Cold Spring Harb Mol Case Stud. 2022 Jun 22;8(4):
pubmed: 35732499
Perit Dial Int. 2015 Dec;35(7):676-7
pubmed: 26703842
Bioinformatics. 2016 Apr 15;32(8):1220-2
pubmed: 26647377
Nat Methods. 2010 Aug;7(8):575-6
pubmed: 20676075
Am J Hum Genet. 2017 Feb 2;100(2):267-280
pubmed: 28132688
Nature. 2020 May;581(7809):444-451
pubmed: 32461652
Nat Genet. 2011 May;43(5):491-8
pubmed: 21478889
Cells. 2020 Jul 27;9(8):
pubmed: 32726939
Nat Commun. 2016 Nov 08;7:13316
pubmed: 27824329
Genet Med. 2022 Sep;24(9):1941-1951
pubmed: 35678782
Nat Neurosci. 2019 Feb;22(2):205-217
pubmed: 30664766
Nat Rev Mol Cell Biol. 2019 Feb;20(2):102-115
pubmed: 30390028
Clin Genet. 1987 Nov;32(5):326-34
pubmed: 3121220
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Nat Neurosci. 2017 Apr;20(4):602-611
pubmed: 28263302
Nature. 2020 Oct;586(7827):80-86
pubmed: 32717741
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894
pubmed: 30371827
Cell. 2022 Nov 10;185(23):4409-4427.e18
pubmed: 36368308
Nat Commun. 2017 Jan 24;8:14061
pubmed: 28117401
Genome Biol. 2021 May 25;22(1):161
pubmed: 34034781
Nucleic Acids Res. 2021 Jul 2;49(W1):W21-W28
pubmed: 34023905
J Genet Genomics. 2018 Oct 20;45(10):527-538
pubmed: 30392784
Nucleic Acids Res. 2011 Sep 1;39(17):e118
pubmed: 21727090
MMWR Surveill Summ. 2018 Apr 27;67(6):1-23
pubmed: 29701730
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Nat Genet. 2019 Jul;51(7):1092-1098
pubmed: 31209396
Annu Rev Genomics Hum Genet. 2020 Aug 31;21:289-304
pubmed: 32396753
NPJ Genom Med. 2021 Feb 9;6(1):8
pubmed: 33563995
Nat Commun. 2022 Oct 29;13(1):6463
pubmed: 36309498
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Neurosci Biobehav Rev. 2021 Sep;128:244-257
pubmed: 34166716
Behav Genet. 2019 Jul;49(4):399-414
pubmed: 30949922
Genome Res. 2011 Jun;21(6):974-84
pubmed: 21324876
Nature. 2020 Jul;583(7814):83-89
pubmed: 32460305
Nat Methods. 2015 Oct;12(10):966-8
pubmed: 26258291
Genome Res. 2018 Apr;28(4):581-591
pubmed: 29535149
Bioinformatics. 2010 Nov 15;26(22):2867-73
pubmed: 20926424
JAMA. 2018 Feb 6;319(5):505
pubmed: 29305599
Genome Biol. 2020 Apr 28;21(1):102
pubmed: 32345345
Neuron. 2013 Jan 23;77(2):235-42
pubmed: 23352160
Hum Mutat. 2022 Apr;43(4):499-510
pubmed: 35112413
Cell. 2020 Feb 6;180(3):568-584.e23
pubmed: 31981491